問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of Nuclear Medicine

Digestive System Department

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

許駿Hsu, Chiun
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

96Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許駿

List

210Cases

2010-11-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2006-01-01 - 2007-12-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2015-08-03 - 2017-03-31

Phase I

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma

  • Condition/Disease

    Advanced or Refractory Solid Tumors or Lymphoma

  • Test Drug

    JNJ42756493

Participate Sites
2Sites

Terminated2Sites

2006-03-01 - 2010-01-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-03-01 - 2014-06-30

Phase II

A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)

  • Condition/Disease

    Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD8931

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2011-12-01 - 2016-07-31

Phase II

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (Shine study)

  • Condition/Disease

    Advanced Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD4547

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2015-07-01 - 2019-03-31

Phase I

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients with Advanced Solid Tumours

  • Condition/Disease

    Advanced Solid Tumours

  • Test Drug

    MEDI4736

Participate Sites
3Sites

Not yet recruiting3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2012-07-01 - 2015-07-31

Phase I

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumor

  • Condition/Disease

    Advance solid tumor/non-small cell lung cancer/astric/gastroesophageal junction adenocarcinoma

  • Test Drug

    ABT-700

Participate Sites
3Sites

Terminated3Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

2016-09-19 - 2018-04-30

Phase I

A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects with Advanced Solid Tumor

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    OPB-111077 100-mg Tablets

Participate Sites
5Sites

Terminated4Sites

2008-05-01 - 2011-12-31

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 11 12 13 14 15 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB